Interstitial in vivo ALA-PpIX mediated metronomic photodynamic therapy (mPDT) using the CNS-1 astrocytoma with bioluminescence monitoring

Summary Background We report the first truly metronomic delivery of photodynamic therapy using the rat-derived CNS-1 astrocytoma, a model with close histopathology with human brain tumours. Methods Metronomic PDT (mPDT) was delivered to CNS-1 bearing female Lewis rats. 5-Aminoluvelinic acid was deli...

Full description

Saved in:
Bibliographic Details
Published in:Photodiagnosis and photodynamic therapy 2007-09, Vol.4 (3), p.202-212
Main Authors: Davies, Nick, BSc (Hons), MSc, Wilson, Brian C
Format: Article
Language:English
Subjects:
5-Aminoluvelinic acid
Acute photodynamic therapy
Apoptosis
Bioluminescence imaging
Glioblastoma multiforme
Hematology, Oncology and Palliative Medicine
Internal Medicine
LED-fiber coupled sources
Malignant astrocytoma
Metronomic photodynamic therapy
Protoporphyrin IX
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background We report the first truly metronomic delivery of photodynamic therapy using the rat-derived CNS-1 astrocytoma, a model with close histopathology with human brain tumours. Methods Metronomic PDT (mPDT) was delivered to CNS-1 bearing female Lewis rats. 5-Aminoluvelinic acid was delivered continuously through drinking water, while light was delivered via tetherless, light-weight, LED-based fiber coupled optical sources. Tumour burden before and after mPDT treatment was determined using bioluminescence imaging (BLI). Results Preliminary studies demonstrated that 24 h of continuous mPDT illumination was capable of destroying small tumours (7 days post-implant). The reduction or elimination of tumour was confirmed using BLI and corroborated by histology. Additional studies showed that 24 and 48 h continuous mPDT illumination had the capability to delay tumour re-growth by a period corresponding to approximately two doubling times. Animals given 4-day mPDT did not show any signs of tumour re-growth via BLI at 26 days post-tumour implantation. Conclusions In summary, these results demonstrate the feasibility of delivering mPDT for extended periods, as well as its potential as a treatment for small brain tumours.
ISSN:1572-1000
1873-1597
DOI:10.1016/j.pdpdt.2007.06.002